DOCSLIB.ORG

3 Intravenous Anaesthetic Agents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
3 Intravenous Anaesthetic Agents F0078-Ch03.qxd 28/08/2006 04:23 PM Page 34 3 Intravenous anaesthetic agents General anaesthesia may be produced by many drugs ● No emetic effects which depress the CNS, including sedatives, tranquil- ● No excitatory phenomena (e.g. coughing, hiccup, lizers and hypnotic agents. However, for some drugs involuntary movement) on induction the doses required to produce surgical anaesthesia are ● No emergence phenomena (e.g. nightmares) so large that cardiovascular and respiratory depres- ● No interaction with neuromuscular blocking drugs sion commonly occur, and recovery is delayed for ● No pain on injection hours or even days. Only a few drugs are suitable for ● No venous sequelae use routinely to produce anaesthesia after intravenous ● Safe if injected inadvertently into an artery (i.v.) injection. ● No toxic effects on other organs Intravenous anaesthetic agents are used commonly ● No release of histamine to induce anaesthesia, as induction is usually ● No hypersensitivity reactions smoother and more rapid than that associated with ● Water-soluble formulation most of the inhalational agents. Intravenous anaes- ● Long shelf-life thetics may also be used for maintenance, either alone ● No stimulation of porphyria. or in combination with nitrous oxide; they may be administered as repeated bolus doses or by continu- None of the agents available at present meets all these ous i.v. infusion. Other uses include sedation during requirements. Features of the commonly used i.v. anaes- regional anaesthesia, sedation in the intensive therapy thetic agents are compared in Table 3.1, and a classifica- unit (ITU) and treatment of status epilepticus. tion of i.v. anaesthetic drugs is shown in Table 3.2. PROPERTIES OF THE IDEAL INTRAVENOUS PHARMACOKINETICS OF INTRAVENOUS ANAESTHETIC AGENT ANAESTHETIC DRUGS ● Rapid onset – this is achieved by an agent which is After i.v. administration of a drug, there is an immedi- mainly unionized at blood pH and which is highly ate rapid increase in plasma concentration followed by soluble in lipid; these properties permit penetration a slower decline. Anaesthesia is produced by diffusion of the blood–brain barrier of drug from arterial blood across the blood–brain bar- ● Rapid recovery – early recovery of consciousness is rier into the brain. The rate of transfer into the brain, usually produced by rapid redistribution of the and therefore the anaesthetic effect, is regulated by the drug from the brain into other well-perfused following factors: tissues, particularly muscle. The plasma Protein binding. Only unbound drug is free to cross concentration of the drug decreases, and the drug the blood–brain barrier. Protein binding may be diffuses out of the brain along a concentration reduced by low plasma protein concentrations or dis- gradient. The quality of the later recovery period is placement by other drugs, resulting in higher concen- related more to the rate of metabolism of the drug; trations of free drug and an exaggerated anaesthetic drugs with slow metabolism are associated with a effect. Protein binding is also affected by changes in more prolonged ‘hangover’ effect and accumulate blood pH. Hyperventilation decreases protein binding if used in repeated doses or by infusion for and increases the anaesthetic effect. maintenance of anaesthesia Blood flow to the brain. Reduced cerebral blood flow ● Analgesia at subanaesthetic concentrations (CBF), e.g. carotid artery stenosis, results in reduced ● Minimal cardiovascular and respiratory depression delivery of drug to the brain. However, if CBF is reduced 34 F0078-Ch03.qxd 28/08/2006 04:23 PM Page 35 INTRAVENOUS ANAESTHETIC AGENTS 3 Table 3.1 Main properties of intravenous anaesthetics Thiopental Methohexital Propofol Ketamine Etomidate Physical properties Water-soluble ++−++a Stable in solution −−+++ Long shelf-life − – +++ Pain on i.v. injection −+++b −++b Non-irritant on s.c. injection − ± ++ Painful on arterial injection ++− No sequelae from intra-arterial injection − ± + Low incidence of venous thrombosis ++++− Effects on body Rapid onset +++++ Recovery due to: Redistribution ++++ Detoxification ++ Cumulation ++ + − − − Induction Excitatory effects − ++ + + +++ Respiratory complications −++−− Cardiovascular Hypotension ++++−+ Analgesic −−−++− Antanalgesic ++−−? Interaction with relaxants −−−−− Postoperative vomiting −−−+++ Emergence delirium −−−++− Safe in porphyria −−++− aAqueous solution not commercially available. bPain may be reduced when emulsion with medium-chain triglycerides is used. because of low cardiac output, initial blood concentra- depends on the degree of ionization at the pH of extra- tions are higher than normal after i.v. administration, cellular fluid and the pKa of the drug. and the anaesthetic effect may be delayed but enhanced. The relative solubilities of the drug in lipid and water. Extracellular pH and pKa of the drug. Only the non- High lipid solubility enhances transfer into the brain. ionized fraction of the drug penetrates the lipid Speed of injection. Rapid i.v. administration results blood–brain barrier; thus, the potency of the drug in high initial concentrations of drug. This increases 35 F0078-Ch03.qxd 28/08/2006 04:23 PM Page 36 INTRAVENOUS ANAESTHETIC AGENTS 100 Table 3.2 Classification of intravenous anaesthetics 80 P o Le Rapidly acting (primary induction) agents o a l n Barbiturates: Methohexital 60 Thiobarbiturates – thiopental, thiamylal % of dose 40 Imidazole compounds – etomidate ra e c is at Sterically hindered alkyl phenols – propofol V F 20 Steroids – eltanolone, althesin, minaxolone (none currently available) 0 1 2 4 8 16 32 128 0.5 Eugenols – propanidid (not currently available) 0.06 0.25 0.125 Slower-acting (basal narcotic) agents min Fig. 3.1 Ketamine Distribution of thiopental after intravenous bolus administration. Benzodiazepines – diazepam, flunitrazepam, midazolam Large-dose opioids – fentanyl, alfentanil, sufentanil, remaining in the body at 24 h. There is also a small remifentanil amount of redistribution to areas with a very poor blood supply, e.g. bone. Table 3.3 indicates some of the Neuroleptic combination – opioid + neuroleptic properties of the body compartments in respect of the distribution of i.v. anaesthetic agents. After a single i.v. dose, the concentration of drug in the speed of induction, but also the extent of cardio- blood decreases as distribution occurs into viscera, vascular and respiratory side-effects. and particularly muscle. Drug diffuses from the brain In general, any factor which increases the blood into blood along the changing concentration gradient, concentration of free drug, e.g. reduced protein bind- and recovery of consciousness occurs. Metabolism of ing or low cardiac output, also increases the intensity most i.v. anaesthetic drugs occurs predominantly in of side-effects. the liver. If metabolism is rapid (indicated by a short Distribution to other tissues Table 3.3 Factors influencing the distribution The anaesthetic effect of all i.v. anaesthetic drugs in of thiopental in the body current use is terminated predominantly by distribu- tion to other tissues. Figure 3.1 shows this distribution Viscera Muscle Fat Others for thiopental. The percentage of the injected dose in each of four body compartments as time elapses is Relative blood flow Rich Good Poor Very shown after i.v. injection. A large proportion of the poor drug is distributed initially into well-perfused organs Blood flow (L min−1) 4.5 1.1 0.32 0.08 (termed the vessel-rich group, or viscera – predomi- nantly brain, liver and kidneys). Distribution into Tissue volume (L; A) 6 33 15 13 muscle (lean) is slower because of its low lipid content, but it is quantitatively important because of its rela- Tissue/blood 1.5 1.5 11.0 1.5 tively good blood supply and large mass. Despite their partition coefficient (B) high lipid solubility, i.v. anaesthetic drugs distribute slowly to adipose tissue (fat) because of its poor blood Potential capacity 9 50 160 20 supply. Fat contributes little to the initial redistribution (L; A × B) or termination of action of i.v. anaesthetic agents, but fat depots contain a large proportion of the injected Time constant (capacity/flow; min) 2 45 500 250 dose of thiopental at 90 min, and 65–75% of the total 36 F0078-Ch03.qxd 28/08/2006 04:23 PM Page 37 BARBITURATES 3 elimination half-life), it may contribute to some extent O H to the recovery of consciousness. However, because of the large distribution volume of i.v. anaesthetic drugs, total elimination takes many hours, or, in some instances, days. A small proportion of drug may be R´ C N excreted unchanged in the urine; the amount depends 6 1 on the degree of ionization and the pH of urine. C 5 2 C O BARBITURATES R 4 3 C N Amobarbital and pentobarbital were used i.v. to induce anaesthesia in the late 1920s, but their actions were unpredictable and recovery was prolonged. R Manipulation of the barbituric acid ring (Fig. 3.2) O enabled a short duration of action to be achieved by: Fig. 3.2 Structure of barbiturate ring. ● substitution of a sulphur atom for oxygen at position 2 out the world. Its pharmacology is therefore described ● substitution of a methyl group at position 1; this fully in this chapter. Many of its effects are shared by also confers potential convulsive activity and other i.v. anaesthetic agents and consequently the increases the incidence of excitatory phenomena. pharmacology of these drugs is described more briefly. An increased number of carbon atoms in the side chains at position 5 increases the potency of the agent. The presence of an aromatic nucleus in an alkyl group THIOPENTAL SODIUM at position 5 produces compounds with convulsant Chemical structure properties; direct substitution with a phenyl group confers anticonvulsant activity. Sodium 5-ethyl-5-(1-methylbutyl)-2-thiobarbiturate. The anaesthetically active barbiturates are classi- fied chemically into four groups (Table 3.4). The Physical properties and presentation methylated oxybarbiturate hexobarbital was moder- ately successful as an i.v. anaesthetic agent, but was Thiopental sodium, the sulphur analogue of pentobar- superseded by the development in 1932 of thiopental.
Load more

Recommended publications
  • Veterinary Anaesthesia (Tenth Edition)
    W. B. Saunders An imprint of Harcourt Publishers Limited © Harcourt Publishers Limited 2001 is a registered trademark of Harcourt Publishers Limited The right of L.W. Hall, K.W. Clarke and C.M. Trim to be identified as the authors of this work have been asserted by them in accordance with the Copyright, Designs and Patents Act, 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without either the prior permission of the publishers (Harcourt Publishers Limited, Harcourt Place, 32 Jamestown Road, London NW1 7BY), or a licence permitting restricted copying in the United Kingdom issued by the Copyright Licensing Agency Limited, 90 Tottenham Court Road, London W1P 0LP. First edition published in 1941 by J.G. Wright Second edition 1947 (J.G. Wright) Third edition 1948 (J.G. Wright) Fourth edition 1957 (J.G. Wright) Fifth edition 1961 (J.G. Wright and L.W. Hall) Sixth edition 1966 (L.W. Hall) Seventh edition 1971 (L.W. Hall), reprinted 1974 and 1976 Eighth edition 1983 (L.W. Hall and K.W. Clarke), reprinted 1985 and 1989 Ninth edition 1991 (L.W. Hall and K.W. Clarke) ISBN 0 7020 2035 4 Cataloguing in Publication Data: Catalogue records for this book are available from the British Library and the US Library of Congress. Note: Medical knowledge is constantly changing. As new information becomes available, changes in treatment, procedures, equipment and the use of drugs become necessary. The authors and the publishers have taken care to ensure that the information given in this text is accurate and up to date.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Proceedings of the Anaesthetic Research Society Glasgow Meeting July 7, 1979
    Br.J. Anaesth. (1979), 51-, 989P PROCEEDINGS OF THE ANAESTHETIC RESEARCH SOCIETY GLASGOW MEETING JULY 7, 1979 EFFECT OF KETAMINE ON TRANSMISSION a 50% depression in the response to carbachol 5.46 x 10~6 1 5 IN SYMPATHETIC GANGLIA mol litre" was determined (IC50 ketamine = 8.5 x 10" 1 mol litre" , r = 0.83). Downloaded from https://academic.oup.com/bja/article/51/10/989/304330 by guest on 29 September 2021 V. MAHMOODI, A. J. BYRNE, T. E. J. HEALY AND In the concentrations used ketamine has been shown to S. Z. HUSSAIN interfere with the sympathetic final common pathway but Department of Surgery {Anaesthesia), Queen's Medical the results do not preclude a central effect at lower con- Centre, University Hospital, Clifton Boulevard, centrations. Nottingham ACKNOWLEDGEMENT An increase in arterial pressure following the injection of We gratefully acknowledge financial support from Parke ketamine is well documented and has been explained by Davis and Co. both central (Ivankovich et al., 1974) and peripheral actions (Nedergaard, 1973). The sympathetic division of REFERENCES the autonomic nervous system is the link between central Hukovic, S. (1961). Br. J. Pharmacol, 16, 188. and peripheral mechanisms for increasing arterial pressure. Ivankovich, A. D., Miletich, D. J., Reimann, C, Albrecht, It was therefore decided to investigate the effects of keta- R. F., and Zahed, B. (1974). Anesth. Analg. {Cleve.), 53, mine on this final common pathway. 924. The hypogastric nerve, hypogastric plexus and vas Nedergaard, O. A. (1973). Eur. J. Pharmacol, 23, 153. deferens of adult guineapigs were dissected (Hukovic, 1961) and mounted in Krebs' solution bubbled with oxygen 95% and carbon dioxide 5% at 32 °C.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Abstract/Summary Development Targets in Anaesthetic
    University of Plymouth PEARL https://pearl.plymouth.ac.uk Faculty of Health: Medicine, Dentistry and Human Sciences Peninsula Medical School 2017-12-01 Thiopental to desflurane - an anaesthetic journey. Where are we going next? Sneyd, J http://hdl.handle.net/10026.1/9849 10.1093/bja/aex328 British Journal of Anaesthesia Oxford University Press (OUP) All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author. Thiopental to desflurane - an anaesthetic journey. Where are we going next? Abstract/summary Development targets in anaesthetic pharmacology have evolved from minimising harm caused by unwanted effects through an era in which rapid onset and offset of drug effect were prioritised. Today’s anaesthetists have access to a library of effective drugs whose characteristics offer controllable hypnosis, analgesia and paralysis with manageable off-target effects. The availability of these agents at generic prices inhibits commercial interest and this is reflected in the limited number of current anaesthetic drug development projects. Recently, questions around neonatal neurotoxicity, delirium and post-operative cognitive dysfunction have stimulated research to characterise these phenomena and explain them in mechanistic terms. Emergent basic science from these enquiries together with exploration of possible effects of anaesthetic drug choice on patient outcomes from cancer surgery may yield new targets for drug discovery. The past 40 years have seen extraordinary developments in anaesthetic pharmacology culminating in a limited but versatile set of hypnotics, analgesics and muscle relaxants adaptable to every clinical situation.
    [Show full text]
  • Eltanolone: 50 Years on and Still Looking for Steroid Hypnotic Agents!
    European Journal of Anaesthesiology 1998, 15, 129±132 EDITORIAL Eltanolone: 50 years on and still looking for steroid hypnotic agents! The knowledge that steroids can induce and maintain sition as the sodium hemisuccinate. Hydroxydione anaesthesia is not new; in 1927, Cashin and Moravek had a high therapeutic index, and few adverse effects caused hypnosis in cats by using a colloidal sus- in cats and dogs [4]. pension of cholesterol [1]. However, present-day in- In clinical practice, hydroxydione produced minimal terest in these molecules stems from the systematic changes in cardiorespiratory function, good muscle review of the hypnotic properties of steroids (mainly relaxation, a low incidence of coughing and pleasant belonging to the pregnane and androstane groups) recovery, with a very low incidence of vomiting [5,6]. by Selye in 1941 [2]. There was no apparent relation However, induction took several minutes. As there between hypnotic (anaesthetic) and hormonal prop- was early obtunding of the pharyngeal and laryngeal erties in any of the screened steroids; the most re¯exes, it was possible to achieve airway intubation. potent anaesthetic steroid, pregnane-3,20-dione The respiratory rate increased with an accompanying (pregnanedione), was virtually devoid of endocrino- decrease in tidal volume and with a resulting increase logical activity. in minute volume. Marked respiratory depression and However, one of the major problems with these apnoea were not usually seen. Cardiac output and steroidal agents was their poor water solubility, and arterial blood pressure also fell. However, there were little further work was conducted until Laubach and several unwanted side effects: pain on injection; and colleagues synthesized hydroxydione [3].
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • The Safety, Efficacy and Neuromotor Effects of the Neurosteroid Anaesthetic Alfaxalone in Rats Cora Lau Bvsc (Hons)
    The Safety, Efficacy and Neuromotor Effects of the Neurosteroid Anaesthetic Alfaxalone in Rats Cora Lau BVSc (Hons) A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in 2013 School of Biomedical Sciences 1 Abstract Rodents are routinely anaesthetised for husbandry and biomedical research purposes. All anaesthetics carry a degree of risk, complications and side effects. An ideal anaesthetic for rodents is safe, predictable, alleviates pain and distress and can be performed without specialist training. A survey was created to identify anaesthetic agents frequently administered to rodents currently utilised by the research community. Findings indicated injectable anaesthetics were very commonly used and complications were often associated with use, highlighting the lack of a safe, predictable laboratory rodent anaesthetic protocol. Alfaxalone is a neuroactive steroid injectable anaesthetic agent with a high margin of safety, and is commonly used in veterinary anaesthesia as the Alfaxan® formulation. I sought to establish whether alfaxalone could be used as an injectable anaesthetic agent for laboratory rodents. A plasma pharmacokinetics study was performed using IV and IP Alfaxan® in adult female Wistar rats (7-10 -1 weeks). Mean T1/2elim for 2 and 5 mg.kg IV was short (~17 minutes), but could not be estimated for IP dosing due to sustained plasma levels for up to 60 minutes after injection. Clp for IV injection was -1 calculated at 24.5% and 23% of cardiac output respectively. The observed Cmax was 2.99 mg.L for IP administration, and 2.2 ± 0.9 and 5.2 ± 1.3 mg.L-1 for 2 and 5 mg.kg-1 IV administration -1 respectively.
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 8,975,245 B2 Goodchild Et A]
    USOO8975245B2 (12) United States Patent (10) Patent N0.: US 8,975,245 B2 Goodchild et a]. (45) Date of Patent: *hlar.10,2015 (54) ANAESTHETIC FORMULATION (56) References Cited (71) Applicant: DraWbridge Pharmaceuticals Pty Ltd, U.S. PATENT DOCUMENTS Southbank (AU) 2003/0055023 A1 3/2003 Rajewski et a1. 2003/0073665 A1 4/2003 Thompson et al. (72) Inventors: Juliet Marguerite Goodchild, Malvem (AU); Colin Stanley Goodchild, FOREIGN PATENT DOCUMENTS Malvern (AU); Benjamin James Boyd, Warrandyte (AU) EP 0399716 Bl 1/1994 W0 WO 93/17711 Al 9/1993 (73) Assignee: DraWbridge Pharmaceuticals Pty Ltd, W0 WO 01/70234 Al 9/2001 Southbank, Victoria (AU) W0 WO 2004/039426 A2 5/2004 OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 Brewster, M.E. et a1. 1989 “Development of a Non-Surfactant For U.S.C. 154(b) by 0 days. mulation for Alfaxalone Through the Use of Chemically-Modi?ed This patent is subject to a terminal dis Cyclodextrins” Journal ofParenteral Science & Technology 43: 262 claimer. 265. Brewster, M.E. et al. 1995 “Preparation, Characterization, and Anes (21) Appl. N0.: 14/069,751 thetic Properties of 2-hydroxypr0pyl-[5-cyclodextrin Complexes of Pregnenolone in Rat and Mouse” Journal of Pharmaceutical Sci (22) Filed: Nov. 1, 2013 ences 84: 1154-1159. Chisari, M. et al. 2009 “The In?uence of Neuroactive Steroid (65) Prior Publication Data Lipophilicity 0n GABAA Receptor Modulation: Evidence for a Low Af?nity Interaction” J Neurophysiol 102: 1254-1264. US 2014/0066417 A1 Mar. 6, 2014 Egan, T.D.
    [Show full text]
  • WO 2017/066626 Al 20 April 2017 (20.04.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/066626 Al 20 April 2017 (20.04.2017) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 9/00 (2006.01) A61K 9/19 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, A61K 47/24 (2006.01) A61K 9/51 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61 47/32 (2006.0V) A61K 31/57 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, A61K 47/36 (2006.01) A61P 25/08 (2006.01) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, A61K 9/10 (2006.0V) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (21) International Application Number: SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, PCT/US20 16/057 120 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (22) International Filing Date: zw. 14 October 2016 (14.10.201 6) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (26) Publication Language: English TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (30) Priority Data: TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 62/242,601 16 October 2015 (16.
    [Show full text]
  • Pharmacology – Intravenous Anesthetic Agents & Dissociatives
    Pharmacology - Intravenous Anesthetic Agents & Dissociatives Lyon Lee DVM PhD DACVA Introduction • The term intravenous anesthetic agents implies inducing anesthesia by drugs administered intravenously. • Advantages of IV anesthesia include rapid and smooth induction of anesthesia, little equipment requirement (syringes, needles, catheters), and easy administration of drugs. • Disadvantages include difficult retrieval of drug once administered, less control of depth and duration of anesthesia, lack of ventilatory support, and poor tolerability in debilitated, dehydrated or toxicated animals. • Details of pharmacokinetics and uptake and metabolism of these agents are beyond the scope of this lecture, but note pharmacokinetic knowledge is essential for safe use of these agents. • Ideal characteristics of IV anesthetics are o high therapeutic index o no toxic metabolites o non-cummulative o potent, so small volume is required for anesthetic induction/maintenance o long shelf life and resistance to microbial contamination o compatible with other dugs o quick and smooth induction and recovery o reversible with specific antagonist o non-allergenic o no cardiopulmonary depression o independent of liver and kidneys for metabolism and excretion o no effect on cerebral blood flow o no endocrinologic effect o no pain on injection o inexpensive • Response to administration of IV anesthetic induction agents depends on o Dose, concentration and speed of administration o Blood volume between injection site and brain o lonization o Protein binding o
    [Show full text]
  • Realising the Therapeutic Potential of Neuroactive Steroid Modulators of the GABAA Receptor Belelli, Delia; Hogenkamp, Derk; Gee, Kelvin W.; Lambert, Jeremy J
    University of Dundee Realising the therapeutic potential of neuroactive steroid modulators of the GABAA receptor Belelli, Delia; Hogenkamp, Derk; Gee, Kelvin W.; Lambert, Jeremy J. Published in: Neurobiology of Stress DOI: 10.1016/j.ynstr.2019.100207 Publication date: 2020 Licence: CC BY-NC-ND Document Version Publisher's PDF, also known as Version of record Link to publication in Discovery Research Portal Citation for published version (APA): Belelli, D., Hogenkamp, D., Gee, K. W., & Lambert, J. J. (2020). Realising the therapeutic potential of neuroactive steroid modulators of the GABA receptor. Neurobiology of Stress, 12, 1-11. [100207]. https://doi.org/10.1016/j.ynstr.2019.100207 A General rights Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain. • You may freely distribute the URL identifying the publication in the public portal. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 24. Sep. 2021 Neurobiology of Stress 12 (2020) 100207 Contents lists available at ScienceDirect Neurobiology of Stress journal homepage: www.elsevier.com/locate/ynstr Realising the therapeutic potential of neuroactive steroid modulators of the T GABAA receptor ∗ Delia Belellia, Derk Hogenkampb, Kelvin W.
    [Show full text]